Purchase this article with an account.
K. Ian, D. Tan, A. Fong, W. Chua; Myopia Progression Follow-Up in Myopic Children After Using NeuroVision’s Neural Vision Correction (NVC) Technology. Invest. Ophthalmol. Vis. Sci. 2009;50(13):3974.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
NeuroVision’s NVCTM technology is a non-invasive, patient-specific, perceptual learning program based on visual stimulation and facilitation of neural connections at the cortical level, involving an internet-based computer generated visual training exercise regime using stimuli based on Gabor patches, to sharpen contrast sensitivity and visual acuity. It was demonstrated that the NVC technology is able to improve under-corrected VA and CSF in Myopic Children. We evaluated the rate of Myopia Progressing in Myopic Singaporean Children who wear habitual under-corrected spectacle prescription following a successful completion of the NVCTM treatment.
33 children aged 7-9 having a myopia refraction of at least -1.0DS in both eyes completed NVC treatment over a period of 3-4 months. After the completion of the treatment, subjects were prescribed with habitual spectacles with highest amount of spherical under-correction that allows for VA 20/40 or better. Subjects’ Myopia progression was checked every 3 months for the first year post treatment and every 6 months for the year after.Investigations included manifest and cycloplegic refraction and axial length measurements
27 subjects completed 12 months follow-up. 23 subjects completed 18 months follow-up. Cycloplegic auto-refraction increased by 0.65D in the first 12 months and by 0.15D in the 6 months after. Cycloplegic subjective refraction increased by 0.50D in the first 12 months and by 0.26D in the 6 months after. Axial length increased by 0.46mm in the first 12 months and by 0.15mm in the 6 months after.
The Myopia progression measured in these children is less than the progression reported in similar age groups of Myopic children in Singapore. A large RCT is now underway to investigate the efficacy of this technology on Myopia progression.
Clinical Trial: :
This PDF is available to Subscribers Only